Peripheral arterial ischemic events in cancer patients.
Thromboembolic complications are the second leading cause of death in cancer patients. In contrast to the large body of literature on venous thromboembolism (VTE), relatively few reports have focused on the pathogenesis, incidence, management and outcomes of arterial thromboembolic events in patients with malignancy. The purpose of this article is to review the current literature on the etiology, mechanisms, and prognosis of arterial thromboembolic events in cancer patients and outline appropriate screening and management guidelines that may help lower the rates of morbidity and mortality related to these events.
Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Saurabh
S
Sanon
Daniel J
DJ
Lenihan
Elie
E
Mouhayar
D000465:Algorithms; D000686:Amyloidosis / Q000150:complications; D000970:Antineoplastic Agents / Q000009:adverse effects; D016736:Antiphospholipid Syndrome / Q000209:etiology; D004921:Erythropoietin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007511:Ischemia / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D009456:Neurofibromatosis 1 / Q000150:complications; D058729:Peripheral Arterial Disease / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications; D011379:Prognosis; D011832:Radiation Injuries / Q000209:etiology; D011994:Recombinant Proteins; D012307:Risk Factors; D013923:Thromboembolism / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D019851:Thrombophilia / Q000209:etiology; D065227:Transfusion Reaction
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin